Inflammatory Bowel Disease · Article 39

When Should Proton Pump Inhibitor Therapy Be Continued Long Term?

Long-term PPI therapy requires a structured, evidence-based clinical approach. This review summarizes the key diagnostic, management, monitoring and decision points for gastroenterology and hepatology practice.

Long-term PPI therapy clinical reference — Related free clinical resource: Endoscopy and Diagnostic Imaging.

Long-term PPI therapy: practical clinical approach

This page focuses on Long-term PPI therapy with emphasis on decisions that change patient care, common pitfalls, and the current evidence base.

External guidance for Long-term PPI therapy

Clinical takeaway: For Long-term PPI therapy, decisions should integrate current guidelines, patient-specific risk, and the evidence summarized below.

Answer in brief: Long-term PPI therapy is appropriate when a continuing indication exists—such as severe erosive esophagitis, Barrett’s esophagus, recurrent peptic ulcer risk requiring gastroprotection, or a clearly documented acid-mediated disorder that relapses off therapy. Patients without a durable indication should periodically be considered for dose reduction or discontinuation; concern about hypothetical adverse effects alone is not a reason to stop a clearly indicated PPI.[1]

The key question is indication, not duration

PPIs are among the most effective therapies in gastroenterology. The right approach is to periodically ask whether the original indication still exists and whether the lowest effective dose is being used—not to impose an arbitrary maximum duration.

Common reasons for long-term treatment

Los Angeles grade C or D erosive esophagitis or recurrent severe erosive disease.
Barrett’s esophagus, where daily PPI is also supported in 2025 AGA surveillance guidance.[2]
Chronic NSAID/antiplatelet exposure in a patient with sufficient ulcer-bleeding risk.
Recurrent peptic ulcer or acid hypersecretory disorders.
Objectively documented GERD that predictably relapses and meaningfully impairs quality of life off therapy.

When deprescribing is reasonable

If a PPI was started empirically for nonspecific symptoms, after hospitalization, or for a problem that has resolved, a step-down trial is reasonable. Many patients can move from twice-daily to once-daily treatment, from daily to on-demand treatment, or discontinue. Temporary rebound acid hypersecretion can occur after stopping.

How to counsel about safety

Observational studies have associated PPIs with kidney disease, infections, fractures, micronutrient abnormalities and other outcomes, but association does not prove causation. ACG guidance emphasizes that high-quality evidence has not established most feared long-term harms and that benefits outweigh theoretical risks when an indication is strong.[1]

Testing and monitoring should be individualized

Routine laboratory screening solely because a patient takes a PPI is not necessary for everyone. Magnesium, B12, iron, renal function and bone health should be assessed when other risk factors or clinical features justify it.

Practical review at each renewal

State the current indication.
Confirm the dose and whether twice-daily therapy remains necessary.
Assess symptom control and alarm features.
Consider step-down if the indication is weak or resolved.
Continue without apology when the indication is strong.

Questions trainees should be able to answer

Which GERD phenotypes usually justify indefinite maintenance?
What is rebound acid hypersecretion?
How should observational PPI safety associations be interpreted?

Frequently asked questions

Are PPIs unsafe long term? They have observational associations with many outcomes, but most causal links remain unproven. Use the lowest effective dose for a valid indication.[1]

Should Barrett’s patients take a PPI? AGA 2025 suggests daily PPI therapy compared with no PPI for prevention of neoplastic progression.[2]

Should everyone on a PPI have B12 and magnesium checked? No. Monitoring should be driven by individual risk and clinical context.

References

1. Katz PO, Dunbar KB, Schnoll-Sussman FH, et al. ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am J Gastroenterol. 2022;117:27-56. doi:10.14309/ajg.0000000000001538.

2. Wani S, Zhou MJ, Sawas T, et al. AGA Clinical Practice Guideline on Surveillance of Barrett’s Esophagus. Gastroenterology. 2025.

3. Thomson ABR. Clinical Pharmacology, Physiology and Pathophysiology: Gastroenterology, Hepatology, and Pancreaticobiliary Disorders. CAPstone Academic Publishers; 2024.

Educational use only. This article is intended for clinicians and trainees and does not replace patient-specific medical judgment or local guidance.

← Back to Clinical Questions